Straits Times Index
3,292.69 +10.64 (+0.32%) Nikkei
38,430.49 +24.83 (+0.06%) Hang Seng
17,763.03 +16.12 (+0.09%) FTSE 100
8,144.13 -2.90 (-0.04%) Bitcoin USD
60,234.52 -3,358.18 (-5.28%) CMC Crypto 200
1,290.33 -48.74 (-3.64%)
scPharmaceuticals Inc. (2SX.F)
| Previous close | 4.2400 |
| Open | 4.2400 |
| Bid | 4.1400 x 0 |
| Ask | 4.2400 x 0 |
| Day's range | 4.2000 - 4.2400 |
| 52-week range | 4.0000 - 11.2000 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 152.78M |
| Beta (5Y monthly) | 0.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection
FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and
- GlobeNewswire
scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Generated 4Q 2023 net FUROSCIX® revenue of $6.1 million, at the upper end of the range provided in January and representing sequential growth of 61% from $3.8 million in 3Q 2023 Generated full-year net FUROSCIX® revenue of $13.6 million, at the upper end of the range provided in January Ended 2023 with cash, cash equivalents and short-term investments of $76 million Company to host investor conference call and webcast today, Wednesday, March 13, at 4:30pm ET BURLINGTON, Mass., March 13, 2024 (GL
- GlobeNewswire
scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024
Management to host conference call and webcast at 4:30 p.m. ETBURLINGTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 13, 2024, to discuss the financial resu
